ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - News) today reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon® (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens. The results were presented over the weekend in Barcelona at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL).
